Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545082 | 0.99 | HTR1A (0.57) | HTR1ADRD2HTR2AMAOAMAOB | |
| SCHEMBL15545832 | 0.86 | HTR1A (0.51) | HTR1ADRD2HTR2AMAOAMAOB | |
| SCHEMBL16559730 | 0.86 | DRD2 (0.51) | HTR1ADRD2HTR2AMAOAMAOB | |
| SCHEMBL15547087 | 0.86 | HTR1A (0.55) | HTR1ADRD2HTR2AMAOAMAOB | |
| SCHEMBL15560216 | 0.86 | DRD2 (0.51) | HTR1ADRD2HTR2AMAOAMAOB | |
| SCHEMBL15545822 | 0.85 | DRD2 (0.64) | HTR1ADRD2HTR2AMEN1KMT2A | |
| SCHEMBL15601679 | 0.84 | HTR1A (0.49) | HTR1ADRD2HTR2AMAOAMAOB | |
| SCHEMBL16553094 | 0.84 | DRD2 (0.49) | HTR1ADRD2HTR2AMAOAMAOB | |
| SCHEMBL16553287 | 0.84 | HTR1A (0.52) | HTR1ADRD2HTR2AHTR7DRD3 | |
| SCHEMBL15546097 | 0.84 | DRD2 (0.52) | HTR1ADRD2HTR2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | HTR1A 24/4885DRD2 53/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.